Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice-Reference-Cited by-同舟云学术

Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice

Published:2016-12-23 Issue:4 Volume:66 Page:451-460
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Kavunja Herbert W.,Lang Shuyao,Sungsuwan Suttipun,Yin Zhaojun,Huang Xuefei^ORCID

Funder

National Cancer Institute (US)

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-016-1948-9.pdf

Reference39 articles.

1. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11:509–524

2. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117:1466–1476

3. Klein L, Kyewski B, Allen PM, Hogquist KA (2014) Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol 14:377–391

4. Uyttenhove C, Maryanski J, Boon T (1983) Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 157:1040–1052

5. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3:999–1005

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposome‐based in situ antigen‐modification strategy for “universal” T‐cell‐receptor engineered T cell in cancer immunotherapy;MedComm;2024-07

2. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma;International Immunopharmacology;2024-03

3. Membrane fusogenic nanoparticle‐based HLA‐peptide‐addressing universal T cell receptor‐engineered T (HAUL TCR‐T) cell therapy in solid tumor;Bioengineering & Translational Medicine;2023-08-07

4. Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application;Cancer Letters;2022-10

5. Nanomaterials and Advances in Tumor Immune-Related Therapy: A Bibliometric Analysis;Journal of Biomedical Nanotechnology;2022-09-01